Dr. Clay Siegall:Creating Groundbreaking Developments In Targeted Cancer Treatments

Improving treatment outcomes for patients suffering with cancer is the goal of Dr. Clay Siegall and the staff at the biotech company Seattle Genetics. Since Dr. Siegall founded the company in 1998, it has risen to become a leader in the development of targeted cancer treatments. These are treatments that destroy cancer cells while doing as little damage as possible to surrounding tissue. Dr. Clay Siegall was motivated to focus on this after seeing a family endure the devastation wrought by other methods that are used to treat cancer in many parts of the world.

 

Dr. Siegall and his team are now making a difference. In 2011, they got FDA approval for the antibody drug conjugate ADCETRIS. It was the first time the FDA had approved a drug of this type. ADCETRIS has improved treatment outcomes for cancer patients dramatically and, thanks to marketing agreements Dr. Siegall negotiated with Pfizer, Genentech, Bayer and others, it’s now used all over the world. Those marketing agreements and the passionate fundraising efforts of Dr. Siegall have helped to generate $1.2 billion for Seattle Genetics. This has helped to keep the facility profitable enough to continue its work.

 

This understanding of the delicate balance between business and research is what sets Dr. Siegall apart. It also led to Ernst & Young voting him ‘Entrepreneur of the Year’ in 2012. In addition to his bachelor’s degree in zoology from the University of Maryland and the Ph.D. from George Washington University in genetics, Dr. Siegall also has an understanding that Seattle Genetics is a business. If he’s unable to keep it profitable, it will go under and he’ll no longer be able to help cancer patients. So as he continues to work to produce the best cancer treatment drugs the world has seen in over a generation, he also remains conscious of the bottom line.

 

Through the work of Dr. Siegall and his staff, cancer patients in 60 countries and growing now have better outcomes from their cancer treatment. But Dr. Siegall and his team at Seattle Genetics are committed to working until can is defeated worldwide.

Leave a Reply

Your email address will not be published. Required fields are marked *